Articles with public access mandates - Lipika GoyalLearn more
Not available anywhere: 5
Protons versus photons for unresectable hepatocellular carcinoma: liver decompensation and overall survival
NN Sanford, J Pursley, B Noe, BY Yeap, L Goyal, JW Clark, JN Allen, ...
International Journal of Radiation Oncology* Biology* Physics 105 (1), 64-72, 2019
Mandates: US National Institutes of Health
Immunology and immunotherapy of cholangiocarcinoma
TF Greten, R Schwabe, N Bardeesy, L Ma, L Goyal, RK Kelley, XW Wang
Nature Reviews Gastroenterology & Hepatology 20 (6), 349-365, 2023
Mandates: US National Institutes of Health
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer
L Goyal, SP Chaudhary, EL Kwak, TA Abrams, AN Carpenter, BM Wolpin, ...
Investigational New Drugs 38, 1533-1539, 2020
Mandates: US National Institutes of Health
Genetics of hepatocellular carcinoma: risk stratification, clinical outcome, and implications for therapy
I Labgaa, S Torrecilla, I Martinez-Quetglas, D Sia
Digestive Disease Interventions 1 (02), 055-065, 2017
Mandates: Swiss National Science Foundation, Government of Spain
Paving a pathway for drug development in HER2-positive biliary tract cancer
CT Chen, L Goyal
The Lancet Oncology 22 (9), 1204-1206, 2021
Mandates: US National Institutes of Health
Available somewhere: 71
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer
CR Ferrone, G Marchegiani, TS Hong, DP Ryan, V Deshpande, ...
Annals of surgery 261 (1), 12-17, 2015
Mandates: US National Institutes of Health
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
GK Abou-Alfa, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ...
The Lancet Oncology 21 (6), 796-807, 2020
Mandates: US National Institutes of Health
Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma
M Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ...
Journal of Clinical Oncology 36 (3), 276-282, 2018
Mandates: US National Institutes of Health
Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial
JE Murphy, JY Wo, DP Ryan, W Jiang, BY Yeap, LC Drapek, ...
JAMA oncology 4 (7), 963-969, 2018
Mandates: US National Institutes of Health
New horizons for precision medicine in biliary tract cancers
JW Valle, A Lamarca, L Goyal, J Barriuso, AX Zhu
Cancer discovery 7 (9), 943-962, 2017
Mandates: US National Institutes of Health, Cancer Research UK, V Foundation, USA
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ...
Cancer discovery 7 (3), 252-263, 2017
Mandates: US National Institutes of Health, Government of Italy, V Foundation, USA …
Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic …
TS Hong, JY Wo, BY Yeap, E Ben-Josef, EI McDonnell, LS Blaszkowsky, ...
Journal of Clinical Oncology 34 (5), 460-468, 2016
Mandates: US National Institutes of Health
Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial
JE Murphy, JY Wo, DP Ryan, JW Clark, W Jiang, BY Yeap, LC Drapek, ...
JAMA oncology 5 (7), 1020-1027, 2019
Mandates: US National Institutes of Health, Pancreatic Cancer Action Network, USA
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ...
Nature medicine 25 (9), 1415-1421, 2019
Mandates: US National Institutes of Health, Cancer Research UK, European Commission …
Targeting the HGF/c-MET pathway in hepatocellular carcinoma
L Goyal, MD Muzumdar, AX Zhu
Clinical Cancer Research 19 (9), 2310-2318, 2013
Mandates: US National Institutes of Health
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
Mandates: US Department of Defense, US National Institutes of Health, V Foundation, USA
Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial
AX Zhu, T Macarulla, MM Javle, RK Kelley, SJ Lubner, J Adeva, ...
JAMA oncology 7 (11), 1669-1677, 2021
Mandates: US National Institutes of Health
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions
T Hato, L Goyal, TF Greten, DG Duda, AX Zhu
Hepatology 60 (5), 1776-1782, 2014
Mandates: US National Institutes of Health
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ...
New England Journal of Medicine 388 (3), 228-239, 2023
Mandates: US National Institutes of Health
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
AR Parikh, EE Van Seventer, G Siravegna, AV Hartwig, A Jaimovich, Y He, ...
Clinical Cancer Research 27 (20), 5586-5594, 2021
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program